Dry powder compositions with magnesium stearate
A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 μm to about 5 μm. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.
1. A dry powder composition for delivery to a subject by inhalation, comprising dry particles comprising acetylsalicylic acid (ASA), or a pharmaceutically acceptable salt thereof, co-micronized with magnesium stearate, wherein the magnesium stearate is in an amount of about 0.05% (w/w) to about 0.5% (w/w) of the dry powder composition, wherein ASA stability maintains 95% or above after exposure to a condition selected from the group consisting of 15-20° C./35-45% RH, 20° C./40% RH, 30° C./60% RH, 40° C./75% RH, and 50° C./75% RH, for two weeks, four weeks, 30 days, a month, six weeks, eight weeks, or 12 months.
2. The dry powder composition of claim 1 , wherein the stearate is in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the dry powder composition, wherein acetylsalicylic acid, or a pharmaceutically acceptable salt thereof, is in an amount of about 50% (w/w) or more of the dry powder composition.
3. The dry powder composition of claim 1 , substantially free of carrier particles.
4. The dry powder composition of claim 1 , wherein the dry particles have a MMAD within a range of about 1 μm to about 5 μm.
5. The dry powder composition of claim 4 , wherein the dry particles have a MMAD within a range of about 2 μm to about 3 μm.
6. The dry powder composition of claim 1 , wherein acetylsalicylic acid, or a pharmaceutically acceptable salt thereof, is in an amount of about 80% (w/w) or more of the dry powder composition.
7. The dry powder composition of claim 1 , wherein the APSD of the dry powder composition as measured by mass deposition at stage 1 to stage 8 of a NGI varies by less than about 10% after the dry powder composition have been stored at 50° C./75% relative humidity for about 30 days when compared with the APSD at time, t, equals zero.
8. The dry powder composition of claim 4 , wherein the MMAD of the dry particles varies by less than about 10% after the dry powder composition have been stored at 50° C./75% relative humidity for about 5 days when compared with the MMAD at time, t, equals zero.
9. The dry powder composition of claim 4 , wherein the dry particles have an MMAD size distribution with a DV90 less than about 6 μm, a DV50 less than about 3 μm, and a DV10 less than about 1 μm.
10. The dry powder composition of claim 9 , wherein the DV90, DV50 and/or DV10 vary less than about 10% after the composition is stored at 50° C./75% relative humidity for about 15 days.
11. A drug delivery system effective to reduce the risk of a thromboembolic event or treat thrombosis, wherein the system comprises the dry powder composition of claim 1 .
12. The drug delivery system of claim 11 , further comprising clopidogrel.
13. A drug delivery system comprising a dry powder inhaler and the dry powder composition of claim 1 .
14. A method of treating or reducing a risk of a thromboembolic event, comprising administering to a subject in need thereof the dry powder composition of claim 1 .
15. The method of claim 14 , wherein the thromboembolic event comprises a myocardial infraction.
16. The method of claim 14 , wherein the thromboembolic event comprises a transient ischemic event.